Furthermore, in 2021, Hill et al. revealed that the mutation of kelch-like ECH-associated protein 1 (KEAP1) could participate in the sensitivity of non-small cell lung cancer (NSCLC) cell lines to artesunate through siRNA and small-molecule inhibitor studies, indicating that the combination of artesunate and nuclear factor erythroid 2-related factor 2 (NRF2) inhibitors could become a novel treatment for patients with NSCLC, especially for those with KEAP1/NRF2 pathway mutations [33]. Here, NFE2L2 is linked to non-small cell lung carcinoma.